RxDoctor Payments Data

Quasar Choudhury, MD

Internal Medicine · New Windsor, NYNPI 1720199961

Payments from drug & device makers

$6,708in general payments, 2019–2025

Across 307 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$990
  • GSK$775
  • Lilly USA, LLC$766
  • AbbVie$727
  • Novo Nordisk$391
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$350
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,693100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,708 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$139,553
Medicare patients
188
Services billed
2,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide76$100,048
EliquisApixaban55$82,250
TrulicityDulaglutide38$55,693
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$52,472
OzempicSemaglutide43$49,598
LinzessLinaclotide27$36,181
JardianceEmpagliflozin29$35,578
JanumetSitagliptin Phos/Metformin Hcl14$16,340
FarxigaDapagliflozin Propanediol11$14,171
Combivent RespimatIpratropium/Albuterol Sulfate11$8,809
Albuterol Sulfate HfaAlbuterol Sulfate139$5,140
Wixela InhubFluticasone Propion/Salmeterol17$4,693
Epinephrine11$4,285
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,958
Levothyroxine Sodium299$3,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$766$155,741114 claims
PfizerEliquis$203$82,25055 claims
GSKTrelegy Ellipta$775$52,47242 claims
Novo NordiskOzempic$391$49,59843 claims
Boehringer IngelheimJardiance, Combivent Respimat$318$44,38740 claims
AbbVieLinzess$727$36,18127 claims
MerckJanumet$62$16,34014 claims
AstraZenecaFarxiga$990$14,17111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$3,781299 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Windsor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →